Monte Rosa Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $9,216 | $4,695 | $1,064 | $8,752 |
Gross Profit | 9,216 | 2,635 | -833 | 6,906 |
EBITDA | -24,424 | -30,582 | -33,049 | -33,017 |
EBIT | -26,527 | -32,642 | -34,946 | -34,863 |
Net Income | -23,859 | -30,310 | -31,968 | -33,252 |
Net Change In Cash | 9,216 | 4,695 | 1,064 | 8,752 |
Free Cash Flow | -21,393 | -29,788 | -39,549 | 27,945 |
Cash | 125,575 | 108,847 | 99,752 | 128,101 |
Basic Shares | 82,011 | 71,233 | 60,156 | 56,927 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -6,222 | -8,559 | -2,132 | -537 |
EBITDA | -137,089 | -99,942 | -70,750 | -27,473 |
EBIT | -143,311 | -108,501 | -72,882 | -28,010 |
Net Income | -135,352 | -104,618 | -71,942 | -36,068 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -291,219 | 308,546 | ||
Free Cash Flow | -62,843 | -105,377 | -69,095 | -26,442 |
Cash | 128,101 | 54,912 | 346,071 | 41,699 |
Basic Shares | 51,396 | 47,227 | 46,535 | 44,002 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.29 |
2024-06-30 | -$0.43 |
2024-03-31 | -$0.53 |
2023-12-31 | -$0.58 |
